CRYOPORT, INC. Deferred Other Tax Expense (Benefit)
CRYOPORT, INC. (CYRX) reported Deferred Other Tax Expense (Benefit) of $8.98 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredOtherTaxExpenseBenefit · last filed 2025-03-07
- CRYOPORT, INC. deferred other tax expense (benefit) for fiscal 2022 was $8.98M, a 36.41% decline from fiscal 2021.
- CRYOPORT, INC. deferred other tax expense (benefit) for fiscal 2021 was $14.13M, a 52.10% increase from fiscal 2020.
- CRYOPORT, INC. deferred other tax expense (benefit) for fiscal 2020 was $9.29M, a 335.65% increase from fiscal 2019.
- CRYOPORT, INC. deferred other tax expense (benefit) for fiscal 2019 was $2.13M.
| Period end | Deferred Other Tax Expense (Benefit) 12 month |
|---|---|
| 2022-12-31 | $8.98M 10-K · filed 2025-03-07 |
| 2021-12-31 | $14.13M 10-K · filed 2024-03-13 |
| 2020-12-31 | $9.29M 10-K · filed 2023-02-28 |
| 2019-12-31 | $2.13M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |